ALS drug QRL-101 tested in small safety study
NCT ID NCT06714396
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 23 times
Summary
This early-phase study tested a single dose of the experimental drug QRL-101 in 12 people with ALS. The main goal was to understand how the drug moves through the body and how it affects nerve signals, while also checking for safety. Participants received either QRL-101 or a placebo, and the study is now complete.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Universitair Medisch Centrum Utrecht
Utrecht, Netherlands, 9728 NZ, Netherlands
Conditions
Explore the condition pages connected to this study.